Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Cardiac biomarker is a protein-based substance that can be quantified for prognostic and diagnostic analysis of heart conditions. Cardiac biomarkers are released into the blood when the heart is suffering from an injury or stress such as lack of oxygen. Measurement of cardiac biomarkers such as cardiac troponin, creatinine kinase, myoglobin, and others are used to diagnose several cardiovascular conditions such as acute coronary syndrome (ACS) and cardiac ischemia.

ACS occurs due to the buildup of plaque in the arteries, which results in the narrowing of artery walls. Plaque rupture leads to a sudden decrease in the amount of oxygenated blood reaching the heart. Shortage of blood supply leads to prolonged chest pain. On the other hand, cardiac ischemia reduces the capability of heart muscles to pump enough blood to meet the requirement of heart cells. Reduced flow of blood causes symptoms such as shortness of breath, chest pain, sweating, and others. Blockage of blood supply for a longer period of time can cause death of the heart cells. This condition is called acute myocardial infarction (AMI) or heart attack. Permanent damage to heart muscles can result in irregular heart contractions also called as arrhythmia, which can be fatal. Cardiac biomarker is an essential tool to detect the presence of ACS or cardiac ischemia in patients and also evaluate the severity of their conditions accurately.

Global Cardiac Biomarkers Market - Impact of the Coronavirus (COVID-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020.

According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 177 million cases and 3.8 million deaths due to COVID-19 were reported till June 20, 2021, across the globe.

Impact of COVID-19 on Demand and Supply of Cardiac Biomarkers

The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors. Biotechnology sector is one such sector that has been majorly impacted by the pandemic.

The COVID-19 pandemic has affected the supply chain logistics of biotechnology industry mainly due to strict lockdown in several regions and also halted many ongoing clinical trials. However, the demand for cardiac biomarkers assay is expected to increase in this COVID-19 pandemic, owing to rising number of cardiovascular conditions associated with COVID-19 disease.

According to the article published in the National Center for Biotechnology Information (NCBI) in March 2021, even though novel coronavirus majorly affects the upper respiratory tract, it also leads to several conditions at a systemic level. Existing co-morbid condition such as a cardiovascular disease becomes more complicated during the course of COVID-19 infection. COVID-19 can cause cardiovascular conditions such as arrhythmia, myocarditis, cardiac injury due to septic shock, and acute coronary syndrome. The same study reveals that viral infections such as COVID-19 promote plaque rupture that leads to cardiovascular conditions such as acute coronary syndrome. Cardiac biomarkers aids in the diagnosis and prognosis of COVID-19 infection, which is expected to fuel the growth of cardiac biomarkers market during the pandemic.

Thus, the impact of the coronavirus (COVID-19) pandemic is expected to fuel the growth of the global cardiac biomarkers market during the forecast period, as cardiac biomarkers may act as a measure to determine the severity and mortality of COVID-19 infection. According to a study published by Nature Journal in March 2021, significant higher levels of cardiac biomarker- troponin has been observed in critically-ill COVID-19 patients.

The global cardiac biomarkers market is estimated to be valued at US$ 4,869.2 Mn in 2021, and is expected to exhibit a CAGR of 10.4% over the forecast period (2021-2028).

request-sample

Cardiac Biomarkers Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 4,869.2 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 10.40% 2028 Value Projection: US$ 9,732.9 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia-modified Albumin (IMA), Others
  • By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Others
  • By Location of Testing: Laboratory Testing, Point of Care Testing
Companies covered:

Abbott Laboratories, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Bio-Rad Laboratories, Danaher Corporation, Randox laboratories, Beckman Coulter, Siemens Healthcare, Becton, Dickinson and Company, BioMerieux, Creative Diagnostics, and Alere Inc.

Growth Drivers:
  • Increasing prevalence of cardiovascular diseases
  • Increasing research and development activities by the market players
Restraints & Challenges:
  • Lack of specificity of cardiac biomarkers
  • Limited sensitivity of some cardiac biomarkers

Figure 1: Global Cardiac Biomarkers Market Share (%) Analysis, By Application, 2021

Cardiac Biomarkers  | Coherent Market Insights

The increasing number of cardiovascular diseases is the major factor that is expected to drive the market growth over the forecast period.

The rising number of cardiovascular disease cases is expected to drive growth of cardiac biomarkers market over the forecast period. For instance, according to the American College of Cardiology Foundation, in 2019, there were approximately 1.05 million people suffering from coronary diseases in the U.S. Moreover, according to the Centers for Disease Control and prevention (CDC) report 2020, around 805,000 Americans have a heart attack every year.

Moreover, increasing number of research and development activities for improving the effectiveness of cardiac biomarkers-based tests is expected to aid in the growth of the market over the forecast period. For instance, in 2019, Ortho Clinical Diagnostics, an American in-vitro diagnostics company, developed a more rapid and accurate assay for the detection of heart attack. This newly developed Vitros High Sensitivity Troponin I Assay is based on the quantitative measurement of troponin, which is a cardiac biomarker.

Rising product launches and approvals is expected to drive the growth of cardiac biomarkers market over the forecast period. For instance, in 2017, F. Hoffmann-La Roche AG received the U.S Food and Drug Administration 510(k) clearance for its product TnT Gen 5 STAT (Elecsys Troponin T Gen 5 STAT), which is a blood test done for the detection of heart attack in high-risk patients such as those who have already experienced a cardiovascular condition in the past.

Global Cardiac Biomarkers Market – Restraints

However, the lack of specificity and the need for a more sensitive cardiac biomarker analysis system may act as a restraint in the growth of cardiac biomarkers market. For instance, according to an article by the American Association for Clinical Chemistry (AACC) in June 2020, use of cardiac biomarkers as point-of-care testing (POCT) requires a high sensitivity diagnostic tool as POCT fails to detect minute levels of cardiac biomarker- troponin. Hence, such assays cannot be used for rapid decision-making as one has to wait for several hours before troponin levels increases in the patient and the system is able to detect it.

Global Cardiac Biomarkers Market – Regional Analysis

On the basis of region, the global cardiac biomarkers market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in the global cardiac biomarkers market over the forecast period, owing to rising number of product approvals. For instance, in 2018, Abbott laboratories, an American medical device company, received the CE mark (which means that this product can be marketed in Europe) by the regulatory authority body European Economic Area (EEA) for its High Sensitive troponin-I blood test. This cardiac biomarker-based diagnostic tool helps in early detection of heart attack in healthy adults.

The rising healthcare funding by the American government to manage cardiovascular diseases is expected to fuel the market growth of cardiac biomarkers. For instance, in 2018, the National Institutes of Health (NIH), U.S made a funding of US$ 2.3 billion for R&D (Research & Development) related to cardiovascular diseases for proper management and early treatment of cardiovascular diseases.

Figure 2: Global Cardiac Biomarkers Market Value (US$ 1,894.1 Mn), by Region, 2021

Cardiac Biomarkers  | Coherent Market Insights

Global Cardiac Biomarkers Market – Competitive Landscape

Major players operating in the global cardiac biomarkers market include Abbott Laboratories, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Bio-Rad Laboratories, Danaher Corporation, Randox laboratories, Beckman Coulter, Siemens Healthcare, Becton, Dickinson and Company, BioMerieux, Creative Diagnostics, and Alere Inc.

Cardiac biomarkers are released into the blood when the muscles of the heart are subjected to damage or stress conditions such as hypoxia. Few commonly used cardiac biomarkers in healthcare include myocardial muscle creatine kinase (CK-MB), troponins (T and I), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, ischemia-modified albumin (IMA), and others. Cardiac biomarkers help in the prevention of cardiovascular diseases by providing means for early detection of cardiovascular conditions such as myocardial infarctions, arrhythmia, acute coronary syndrome, cardiac ischemia, and others.

Market Dynamics

Market players and the research-based health organizations are conducting clinical trials for analyzing the potential uses of cardiac biomarkers in the prognosis, diagnosis, and management of cardiovascular diseases. For instance, a clinical study of 263 participants was initiated by the Babcock University, Nigeria, in December 2019 to predict the onset of preeclampsia and predict the risk of cardiovascular diseases using cardiac biomarkers. Preeclampsia is a complication that occurs in pregnant women and is characterized by high blood pressure. This study is expected to be completed by November 2025. Preeclampsia is considered as a risk factor that may lead to stroke and other cardiovascular diseases, thus cardiac biomarkers plays a major role in early prediction of such diseases and in providing early preventive care to women at a risk of acquiring these diseases. This could contribute to the growth of the cardiac biomarkers market over the forecast period.

Market players are focusing on the launch of new products, which is expected to strengthen their position in the global cardiac biomarkers market. For instance, in March 2017, Fujirebio Europe, an in-vitro diagnostic company, launched two of their products Lumipulse G hs Troponin I and Lumipulse G Myoglobin immunoassays, for quantitative measurement of troponin cardiac biomarker and myoglobin cardiac biomarker respectively. Measurement of these cardiac biomarkers helps in diagnosis of acute myocardial infarction (AMI) within 35 minutes.

Market players are involved in business strategies such as mergers and acquisitions to enhance the distribution of cardiac biomarker products, this is expected to drive the growth of the cardiac biomarkers market. For instance, in October 2017, Abbott Laboratories, an American medical device company, and Alere Inc., a rapid point-of-care diagnostic test kit manufacturer based in Massachusetts, U.S., announced the completion of the merger and acquisition deal between them. This deal would enable Abbott Laboratories to expand its global reach, especially with regards to its point-of-care testing products portfolio.

Key features of the study:

  • This report provides an in-depth analysis of global cardiac biomarkers market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global cardiac biomarkers market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Abbott Laboratories, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Bio-Rad Laboratories, Danaher Corporation, Randox laboratories, Beckman Coulter, Siemens Healthcare, Becton, Dickinson and Company, BioMerieux, Creative Diagnostics, and Alere Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global cardiac biomarkers market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global cardiac biomarkers market

Detailed Segmentation:

  • Global Cardiac Biomarkers Market, By Product Type:
    • Myocardial Muscle Creatine Kinase (CK-MB)
    • Troponins (T and I)
    • Myoglobin
    • Brain Natriuretic Peptide (BNPs) or NT-proBNP
    • Ischemia-modified Albumin (IMA)
    • Others
  • Global Cardiac Biomarkers Market, By Application:
    • Myocardial Infarction
    • Congestive Heart Failure
    • Acute Coronary Syndrome
    • Atherosclerosis
    • Others
  • Global Cardiac Biomarkers Market, By Location of Testing:
    • Laboratory Testing
    • Point-of-Care Testing
  • Global Cardiac Biomarkers Market, By Region:
    • North America
      • By Product Type:
        • Myocardial Muscle Creatine Kinase (CK-MB)
        • Troponins (T and I)
        • Myoglobin
        • Brain Natriuretic Peptide (BNPs) or NT-proBNP
        • Ischemia-modified Albumin (IMA)
        • Others
      • By Application:
        • Myocardial Infarction
        • Congestive Heart Failure
        • Acute Coronary Syndrome
        • Atherosclerosis
        • Others
      • By Location of Testing:
        • Laboratory Testing
        • Point of Care Testing
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Product Type:
        • Myocardial Muscle Creatine Kinase (CK-MB)
        • Troponins (T and I)
        • Myoglobin
        • Brain Natriuretic Peptide (BNPs) or NT-proBNP
        • Ischemia-modified Albumin (IMA)
        • Others
      • By Application:
        • Myocardial Infarction
        • Congestive Heart Failure
        • Acute Coronary Syndrome
        • Atherosclerosis
        • Others
      • By Location of Testing:
        • Laboratory Testing
        • Point of Care Testing
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product Type:
        • Myocardial Muscle Creatine Kinase (CK-MB)
        • Troponins (T and I)
        • Myoglobin
        • Brain Natriuretic Peptide (BNPs) or NT-proBNP
        • Ischemia-modified Albumin (IMA)
        • Others
      • By Application:
        • Myocardial Infarction
        • Congestive Heart Failure
        • Acute Coronary Syndrome
        • Atherosclerosis
        • Others
      • By Location of Testing:
        • Laboratory Testing
        • Point of Care Testing
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type:
        • Myocardial Muscle Creatine Kinase (CK-MB)
        • Troponins (T and I)
        • Myoglobin
        • Brain Natriuretic Peptide (BNPs) or NT-proBNP
        • Ischemia-modified Albumin (IMA)
        • Others
      • By Application:
        • Myocardial Infarction
        • Congestive Heart Failure
        • Acute Coronary Syndrome
        • Atherosclerosis
        • Others
      • By Location of Testing:
        • Laboratory Testing
        • Point of Care Testing
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product Type:
        • Myocardial Muscle Creatine Kinase (CK-MB)
        • Troponins (T and I)
        • Myoglobin
        • Brain Natriuretic Peptide (BNPs) or NT-proBNP
        • Ischemia-modified Albumin (IMA)
        • Others
      • By Application:
        • Myocardial Infarction
        • Congestive Heart Failure
        • Acute Coronary Syndrome
        • Atherosclerosis
        • Others
      • By Location of Testing:
        • Laboratory Testing
        • Point of Care Testing
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type:
        • Myocardial Muscle Creatine Kinase (CK-MB)
        • Troponins (T and I)
        • Myoglobin
        • Brain Natriuretic Peptide (BNPs) or NT-proBNP
        • Ischemia-modified Albumin (IMA)
        • Others
      • By Application:
        • Myocardial Infarction
        • Congestive Heart Failure
        • Acute Coronary Syndrome
        • Atherosclerosis
        • Others
      • By Location of Testing:
        • Laboratory Testing
        • Point of Care Testing
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Abbott Laboratories*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Hoffmann-La Roche AG
    • Thermo Fisher Scientific
    • Bio-Rad Laboratories
    • Danaher Corporation
    • Randox laboratories
    • Beckman Coulter
    • Siemens Healthineers
    • Becton, Dickinson and Company
    • BioMerieux
    • Creative Diagnostics
    • Alere Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Application
      • Market Snippet, By Location of Testing
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Porter’s Analysis
    • Industry Trends
    • Pipeline Analysis
    • Key Highlights
    • Epidemiology
    • Regulatory Scenario
    • Global Supply Chain Analysis
  4. Global Cardiac Biomarkers Market - Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Epidemiology
    • Impact of COVID-19 on Demand and Supply of Cardiac Biomarkers
    • Impact of Covid-19 on the Cardiac Biomarkers Market
  5. Global Cardiac Biomarkers Market, By Product Type, 2017-2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 - 2028
      • Segment Trends
    • Myocardial Muscle Creatine Kinase (CK-MB)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Troponins (T and I)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Myoglobin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Brain Natriuretic Peptide (BNPs) or NT-proBNP
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Ischemia-modified Albumin (IMA)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  6. Global Cardiac Biomarkers Market, By Application, 2017 - 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 - 2028
      • Segment Trends
    • Myocardial Infarction
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Congestive Heart Failure
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Acute Coronary Syndrome
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Atherosclerosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  7. Global Cardiac Biomarkers Market, By Location of Testing, 2017 - 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 - 2028
      • Segment Trends
    • Laboratory Testing
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Point-of-Care Testing
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  8. Global Cardiac Biomarkers Market, By Region, 2017 - 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018 - 2028
      • Regional Trends
    • North America
      • Market Size and Forecast, By Product Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Application, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Location of Testing, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Product Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Application, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Location of Testing, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Product Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Application, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Location of Testing, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Application, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Location of Testing, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Product Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Application, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Location of Testing, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Application, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Location of Testing, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Company Profiles
      • Abbott Laboratories*
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Hoffmann-La Roche AG
      • Thermo Fisher Scientific
      • Bio-Rad Laboratories
      • Danaher Corporation
      • Randox laboratories
      • Beckman Coulter
      • Siemens Healthineers
      • Becton, Dickinson and Company
      • BioMerieux
      • Creative Diagnostics
      • Alere Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

  • Analyst Views
  1. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 35 market data tables and 30 figures on “Cardiac Biomarkers Market” - Global Forecast to 2028.

FAQgrowicon

Frequently Asked Questions

The global cardiac biomarkers market is expected to exhibit a CAGR of 10.40% during the forecast period (2021-2028).
The market is estimated to be valued at US$ 4,869.2 Mn in 2021.
Abbott Laboratories, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Bio-Rad Laboratories, Danaher Corporation, Randox laboratories, Beckman Coulter, Siemens Healthcare, Becton, Dickinson and Company, BioMerieux, Creative Diagnostics, and Alere Inc. are some of the prominent players operating in the market.
The market is expected to be valued at US$ 9,732.9 Mn in 2028.
North America is the prominent region in the market.
Increasing number product launches, rising cases of cardiovascular diseases, increasing research and development activities by the market players, and increasing strategic collaborations among the market players are some of the driving factors, which are expected to drive growth of the market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.